Preventive Program in Multiple Sclerosis
27 de enero de 2021 actualizado por: Kamila Řasová
Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
This study monitor the immediate and persistent impact of a preventive complex six-month program specifically developed for newly diagnosed people with multiple sclerosis on fatigue, mental and physical fitness, and quality of life.
The study determined whether changes in clinical function are related to changes in neurohormones, and whether the effect of therapy is dependent on the active approach of study participants.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
The patients who were newly diagnosed with MS underwent a six-month preventive comprehensive program, which included individual physiotherapy focused on the treatment of functional disorders of the loco-motor system and therapy on a neurophysiological basis, group psychotherapy and controlled aerobic training.
The participants were examined three times - before the start of the physiotherapy program, immediately after its completion and six months apart.
Influence on physical fitness (spiroergometric examination), fatigue (Modify Fatigue Impact Scale, fatigue scale for motor and cognitive functions), depression (Beck scale for evaluation of depression), admission of disease RS (Inventory of admission of multiple sclerosis, quality of life) life and selected neurohormones (dehydroepiandrosterone-DHEA, dehydroepiandrosterone sulphate - DHEAS, cortisol).
Tipo de estudio
Intervencionista
Inscripción (Actual)
17
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Praha, Chequia, 128 00
- Kamila Řasová
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 70 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- definite MS
- stable clinical status in the preceding 3 months
- imumnomodulatory treatment for at least two years (including glatiramer acetate, interferon beta-1a, 1b, mitoxantrone, fingolimod, natalizumab)
- Expanded Disability Status Scale (EDSS)≤6
- predominant motor impartment
- six months or more without any physiotherapy
- ability to undergo ambulatory physiotherapy
Exclusion Criteria:
- other neurological disease or conditions disabling movement
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
|
Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes.
Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Questionnaires - The Fatigue scale for motor and cognitive functions
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
FSMC - is an assessment of MS-related cognitive and motor fatigue.
A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question.
Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue).
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - The Satisfaction With Life Scale
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
The scale measures the current level of satisfaction with one's own life.
Investigators express the extent to which they agree or disagree with the five statements.
The rating scale contains 7 points (1- "strongly disagree" and 7 - "strongly agree").
The maximum number of points on the scale is 35 (maximum satisfaction with your life) and the minimum number of points is 5 (dissatisfaction with your life).
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - Multiple Sclerosis Acceptance Questionnaire
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
This questionnaire consists of 20 statements that relate to the lives of patients with MS.
The rating scale has seven points (1- "never pays" to 7 - "always pays").
The minimum value is 20 (minimum adaptation to the diagnosis of MS for a large limitation of the normal life of MS) and the maximum value is 140 points (maximum adaptation to the diagnosis of MS - without the limitation of the normal life of MS) .
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - Beck Depression Inventory Score
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
questionnaire is divided into thirteen categories and patients select a statement in each category which best fits their current feelings on the scale ranged from 0 (the best feelings) to 3 (the worst feelings).
The maximum value of the total scale is 39 and shows the worst feeling of the person.
|
change after six months of the program and after next six moths without therapy is being assessed
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Ventilation capacity
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
Forced vital capacity = FVC [ l ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Metabolic utilization
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
maximal muscle performance = Rmax [ Watt kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Maximal oxygen uptake
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
VO2 kg-1 [ VO2max.kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Maximal oxygen pulse
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
VO2 HR-1 kg-1 [ VO2max.TF-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Relative ventilation
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
[ VEmax.kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Cortisol
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of cortisol [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Cortizone
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of cortisone[ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Dehydroepiandrosterone (DHEA)
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
7β-hydroxydehydroepiandrosterone (7β-OH-DHEA )
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of 7β-OH-DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
7-oxo dehydroepiandrosterone (7-oxo-DHEA )
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of 7-oxo-DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Questionnaires - Modified Fatigue Impact Scale
Periodo de tiempo: change after six months of the program and after next six moths without therapy is being assessed
|
This scale consists of 21 statements that describe how often fatigue has affected a person during last four weeks.
Each statement is ranged from 0 (never) to 4 (almost, always).
The maximum value of the scale is 84.
|
change after six months of the program and after next six moths without therapy is being assessed
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Kamila Řasová, Ph.D., Third Faculty of Medicine Charles University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de octubre de 2017
Finalización primaria (Actual)
1 de octubre de 2019
Finalización del estudio (Actual)
1 de octubre de 2019
Fechas de registro del estudio
Enviado por primera vez
20 de noviembre de 2020
Primero enviado que cumplió con los criterios de control de calidad
9 de diciembre de 2020
Publicado por primera vez (Actual)
14 de diciembre de 2020
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
1 de febrero de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
27 de enero de 2021
Última verificación
1 de enero de 2021
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- EK-VP/25/0/2014
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .